Acute Myeloid Leukemia (AML) Market Insights & Epidemiology Analysis & Forecasts, 2018-2020 & 2021-2030: Major Markets, Marketed Therapies, Emerging Therapies, Case Reports, Patient Journey
Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML)- Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
The total number of incident cases of Acute Myeloid Leukemia (AML) associated in 7MM countries was 41,715 in 2020.
The Acute Myeloid Leukemia (AML) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Acute Myeloid Leukemia (AML) symptoms market size from 2018 to 2030 segmented by seven major markets.
The report also covers current Acute Myeloid Leukemia (AML) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.
Acute Myeloid Leukemia (AML) Drug Chapters
The Acute Myeloid Leukemia (AML) report's drug chapter segment encloses the detailed analysis of Acute Myeloid Leukemia (AML) early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the Acute Myeloid Leukemia (AML) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Acute Myeloid Leukemia (AML) Emerging Drug
Devimistat (CPI-613): Rafael Pharmaceuticals Inc.
Rafael Pharmaceutical's first-in-class clinical lead compound, CPI-613 (devimistat), targets enzymes involved in cancer cell energy metabolism and is located in the mitochondria of cancer cells. CPI-613 is being evaluated in multiple Phase I, I/II, II, and III clinical studies as a single agent and combined with standard drug therapies in patients diagnosed with advanced solid tumors or blood cancers. Enrolment is currently underway in a Phase III clinical trial in r/r AML.
Crenolanib: Arog Pharmaceuticals
Crenolanib besylate is an investigational inhibitor being developed by AROG Pharmaceuticals, LLC. The compound is currently being evaluated for safety and efficacy in clinical trials for various types of cancer, including AML, gastrointestinal stromal tumor (GIST), and glioma.
Crenolanib is an orally bioavailable benzimidazole that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTK) FLT3 (FMS-like Tyrosine Kinase 3), PDGFR (Platelet-Derived Growth Factor Receptor), and PDGFR. Unlike most RTK inhibitors, crenolanib is a type I mutant-specific inhibitor that preferentially binds to phosphorylated active kinases with the 'DFG in' conformation motif.
Acute Myeloid Leukemia (AML) Market Outlook
The report's Acute Myeloid Leukemia (AML) market outlook helps build a detailed comprehension of the historic, current, and forecasted Acute Myeloid Leukemia (AML) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Acute Myeloid Leukemia (AML) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to clearly view the market at first sight.
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 Acute Myeloid Leukemia (AML) Market Overview at a Glance
Market Share (%) Distribution of Acute Myeloid Leukemia in 2018
Market Share (%) Distribution of Acute Myeloid Leukemia in 2030
4 Executive Summary of Acute Myeloid Leukemia (AML)
5 Disease Background and Overview
Introduction
Classification
Symptoms
Causes
Risk Factors
Pathophysiology
Gene mutations Associated With AML
Diagnosis
Diagnostic Algorithm
Diagnostic Guidelines
Prognosis Factors
Treatment
Treatment Guideline
AML in Adult Patients: ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
6 Epidemiology and Patient Population
Key Findings
7MM Total Incident Population of Acute Myeloid Leukemia
Epidemiology of Acute Myeloid Leukemia
The United States
Incidence of AML in the United States
Gender-specific cases in the United States
Age-specific cases in the United States
Genetic Mutations in AML in the United States
EU5
Germany
France
Italy
Spain
United Kingdom
Japan
7 Organizations contributing towards Acute Myeloid Leukemia (AML)
8 Case Reports
9 Patient Journey
10 Marketed Therapies
Daurismo (Glasdegib): Pfizer
IDHIFA (Enasidenib): Bristol Myers Squibb
TIBSOVO (Ivosidenib): Agios Pharmaceuticals
VENCLEXTA (Venetoclax): Abbvie
VYXEOS (Daunorubicin and Cytarabine): Jazz Pharmaceuticals
XOSPATA (Gilteritinib): Astellas Pharma
MYLOTARG (Gemtuzumab ozogamicin): Pfizer
RYDAPT (Midostaurin): Novartis Oncology
VANFLYTA (Quizartinib): Daiichi Sankyo
ONUREG (Azacitidine): Bristol Myers Squibb
11 Emerging Therapies
Key-Cross: Emerging drugs
Induction and Maintenance drugs
Drugs for Relapsed Patients
Other Assets
Inqovi (ASTX727 [Decitabine and cedazuridine]): AstraZeneca/Astex Pharmaceuticals, Inc.
Dociparstat sodium (DSTAT, CX-01): Chimerix
Pevonedistat (TAK-924, MLN4924): Takeda
Devimistat (CPI-613): Rafael Pharmaceuticals Inc.
Radgocitabine (DFP-10917): Delta-Fly Pharma
Uproleselan: GlycoMimetics Incorporated
Bemcentinib: BerGenBio ASA
Flotetuzumab (MGD006): MacroGenics
SNDX-5613: Syndax Pharmaceuticals
Crenolanib: Arog Pharmaceuticals
Olutasidenib (FT-2102): Forma Therapeutics
Galinpepimut-S: Sellas Life Sciences Group
Iomab-B: Actinium Pharmaceuticals
12 Other Promising Therapies
Brequinar: Clear Creek Bio Inc.
CCS1477: CellCentric Ltd.
Aspacytarabine (BST-236): Biosight Ltd.
Azacitidine and Cedazuridine (ASTX030): Astex Pharmaceuticals, Inc.
CA-4948: Curis, Inc.
NEXI-001: NexImmune Inc.
OPB-111077: Immunomedics, Inc.
Alvocidib: Sumitomo Dainippon Pharma Co., Ltd.
Ruxolitinib: Incyte Corporation
Eprenetapopt (APR-246): Aprea Therapeutics
DCP-001: Immunicum/DCPrime BV
GTB-3550 (OXS-3550): GT Biopharma, Inc.
HM43239: Hanmi Pharmaceutical Company Limited
Onvansertib (PCM-075): Cardiff Oncology
Prexigebersen (Liposomal Grb2 Antisense, BP1001): Bio-Path Holdings
Lintuzumab-Ac225 (Actimab-A/Ac-225): Actinium Pharmaceuticals
APVO436: Aptevo Therapeutics
FLYSYN: Synimmune GmbH
GEM333: GEMoaB Monoclonals
IMGN632: ImmunoGen, Inc.
MLM-CAR44.1 T-Cells (CD44v6): AGC Biologics S.p.A.
PRGN-3006: Precigen, Inc.
Sabatolimab (MBG453): Novartis Pharmaceuticals
Vibecotamab (XmAb14045): Xencor, Inc./Novartis
GSPT1 CELMoD (CC-90009): Celgene/Bristol Myers Squibb
13 Acute Myeloid Leukemia (AML): Seven Major Market Analysis
Key Findings
Market Size of Acute Myeloid Leukemia (AML) in 7MM
Market Outlook
United States Market Size
EU-5 Market Size
Germany
France
Italy
Spain
United Kingdom
Japan
For more information about this report visit https://www.researchandmarkets.com/r/i31y0r
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900